LOS ANGELES, January 20, 2015– Verde Media Group Inc. (OTC: VMGI) announces that the companies ordered asset valuation for each of the three divisions is near completion.
The Company has been approached for the products, IP, and distribution rights of Beautyject Inc., offered the ability to leverage them into the strongest strategic hands that will deliver the maximum added value, for both the interested parties shareholders, and Verdes shareholders.
In preparation of the completed valuation management has commenced the process to come to terms on a deal for BeautyJect Inc. a majority owned asset of Verde Media Biotechnology Inc., and integral part of the Biotech Division.
The current internal terminal value calculations for the Beautyject Inc. corporation using a 5.0% growth rate, projected free cash flow of $52mm and a discount rate of 35%, is $175mm with a conservative industry 2.8x EBITDA terminal value multiple.
Beautyject Inc. will produce needle-free, over-the-counter cosmetic B-Ject devices, delivering a revolutionary anti aging system that fights wrinkles in the comfort of your home.
William Veve CEO of Verde Media Group Inc., stated, "We are continuing to negotiate the strategic options with the interested party in order to monetize the IP, technology assets, and distribution rights for Beautyject Inc., upon completion of the asset valuation the terms of the deal with be announced to our shareholders."
About Beautyject Inc.
Beautyject Inc. is a majority owned subsidiary of Verde Biotechnology Corp. and offers needle-free technology fully adapted to the beauty care and cosmetic markets. The injectors can be used to administer liquid cosmetic products such as, hyaluronic acid, vitamins, and a variety of other products delivered to the top layers of the skin through a non-invasive, needle-free, painless delivery system.
For more information, visit: www.beautyject.com
